The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)

Trial Profile

The Safety and Efficacy of Belatacept, Antithymocyte Globulin, and Sirolimus in Recipients of Non-HLA-identical Living-donor Renal Transplants (ITN023ST)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2017

At a glance

  • Drugs Belatacept (Primary) ; Antithymocyte globulin; Daclizumab; Methylprednisolone; Sirolimus
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Acronyms BESTT
  • Most Recent Events

    • 04 Nov 2011 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 27 Apr 2010 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 14 Apr 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top